Eurobio Scientific: Public delisting offer by EB Development

EB Development, the majority shareholder of Eurobio Scientific, plans to launch a tender offer followed by a mandatory delisting at a price of €25.30 per share. This move follows the publication of the half-year results scheduled for September 24, 2026. Currently, EB Development holds 90.14% of the company's shares and voting rights. The offer includes a premium of between 16.05% and 26.39% compared to recent average share prices.

An ad hoc committee of the Board of Directors has been formed to oversee the process, with the firm Ledouble appointed as the independent expert. Completion of the offer is contingent upon filing with the Autorité des marchés financiers (AMF) and regulatory compliance. Minority shareholders will be compensated at the same price as part of the mandatory delisting.